ChinaAMC Innovative Drugs(03525.HK) up 0.66%, biotech policy support
- As of 13:20 HKT on October 12, 2026, ChinaAMC Innovative Drugs (03525.HK) rose 0.66% to HK$9.870.
- The ETF tracks the FTSE ETF Connect Innovative Drugs Index, covering innovative drug companies in Hong Kong and developed markets, with assets of HK$625 million.
NewTimeSpace News:As of 13:20 HKT on October 12, 2026, ChinaAMC Innovative Drugs (03525.HK) traded at HK$9.870, up 0.66%, with turnover of HK$19,700.
NewTimeSpace has learned that ChinaAMC Innovative Drugs (03525.HK) is managed by China Asset Management (Hong Kong) and tracks the FTSE ETF Connect Innovative Drugs Index, which covers innovative drug companies in Hong Kong and developed markets. As of 13:20 HKT on October 12, 2026, the ETF had assets of HK$625 million, a net asset value of HK$9.845 per unit and a board lot of 100 units.
On the news front, the Central Committee of the Communist Party of China and the State Council recently issued the Opinions on Developing New Quality Productive Forces, which calls for accelerating the development of strategic emerging industries including biomedicine and building them into new pillar industries, and for organising major science and technology programmes for people's health and strengthening the role of enterprises in research and development.
Open Source Securities noted that, as Chinese innovative drug makers strengthen their R&D capabilities, clinical development efficiency and platform technologies, Chinese innovative assets are entering the pipelines of global multinational drugmakers at a faster pace, and licensing-out has become an important route for innovative drug companies to realise asset value and expand globally; outbound cooperation is upgrading from single-product licensing to deeper collaboration such as multi-target, multi-platform and joint drug discovery.
